Want to join the conversation?
$KMB 2Q15 Call: Cash provided by operations in 2Q15 was healthy at $772MM compared to year ago quarter, that was down $70MM, driven by the spin-off of the healthcare business. Adjusted return on invested capital, half-way through the year, we’re up 220BP including benefits from spin-off. We expect full year improvement on ROIC to be at least 250BP.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?